Daily Cosmetic Research Analysis
Three impactful studies span safety, mechanistic innovation, and translational dermatology. A U.S. outbreak investigation links Fusarium meningitis to epidural anesthesia for mostly cosmetic procedures in Matamoros, informing diagnostics and therapy. Cutting-edge work introduces a gender-specific human skin-on-a-chip revealing sex hormone effects, while mesenchymal stem cell small EVs modulate epidermal barrier via sphingosine-1-phosphate signaling.
Summary
Three impactful studies span safety, mechanistic innovation, and translational dermatology. A U.S. outbreak investigation links Fusarium meningitis to epidural anesthesia for mostly cosmetic procedures in Matamoros, informing diagnostics and therapy. Cutting-edge work introduces a gender-specific human skin-on-a-chip revealing sex hormone effects, while mesenchymal stem cell small EVs modulate epidermal barrier via sphingosine-1-phosphate signaling.
Research Themes
- Safety of cosmetic procedures and medical tourism
- Sex-specific skin physiology and organ-on-a-chip innovation
- Extracellular vesicle therapeutics and sphingolipid signaling in skin
Selected Articles
1. Biomimetic gender-specific human skin model based on gonads/epidermis-on-a-chip.
This study establishes a human gonads/epidermis-on-a-chip that couples ex vivo epidermis with gonadal cell aggregates, enabling sex hormone crosstalk studies. Estradiol increased keratinocyte proliferation and reduced apoptosis, whereas testosterone promoted differentiation and hyperkeratosis, mirroring known sex differences. The platform supports sex-specific testing for cosmetic and biomedical applications.
Impact: Introduces a gender-specific human skin-on-a-chip that captures endocrine-epidermal crosstalk, a critical gap in preclinical testing. The model mechanistically explains sex differences and enables sex-aware evaluation of skin products and drugs.
Clinical Implications: This platform can reduce animal testing, inform sex-specific safety and efficacy profiling of dermatologic drugs and cosmetic ingredients, and guide personalized skin-care strategies.
Key Findings
- Developed a microfluidic gonads/epidermis-on-a-chip integrating ex vivo human epidermis with gonadal cell aggregates.
- Estradiol enhanced keratinocyte proliferation and reduced apoptosis in the epidermis.
- Testosterone promoted keratinocyte differentiation and induced epidermal hyperkeratosis, aligning with known sex differences.
Methodological Strengths
- Human ex vivo tissue integrated into a controlled organ-on-a-chip microfluidic platform.
- Physiologically relevant hormone exposures with direct readouts of proliferation, apoptosis, and differentiation.
Limitations
- Model lacks full-thickness dermal components, vasculature, and appendages.
- Donor variability and quantitative hormone pharmacokinetics were not fully characterized.
Future Directions: Integrate dermal/vascular compartments and appendages, validate across diverse donors and hormone ranges, and apply to regulatory-grade testing of cosmetic ingredients and dermatologic therapeutics.
The development of bionic skin is crucial for progressing our understanding of skin physiology and pathologies, while the precise replication of human skin features in skin models remains a challenge. In this study, we present a biomimetic, gender-specific skin model utilizing a gonads/epidermis-on-a-chip platform. This innovative approach seamlessly integrates ex vivo cultured human epidermal tissue and gonad cell aggregates into a microfluidic system, facilitating the exploration of the regulatory effects of sex hormones on the epidermis. Based on this platform, we have found that estradiol can enhance proliferation and inhibit apoptosis of keratinocytes. Conversely, testosterone notably induces keratinocyte differentiation, leading to epidermal hyperkeratosis. These observations align with the well-documented phenomenon that males possess thicker and more durable skin, while females' skin exhibits superior repair capabilities. Thus, we believe that our biomimetic gender-specific skin model can offer a promising avenue for obtaining higher-certainty evidence of human skin-related conditions and find important applications in the areas of cosmetics and biomedicine.
2. Fungal meningitis in U.S. Patients who Received Epidural Anesthesia in Matamoros, Mexico.
Among 233 potentially exposed U.S. residents who underwent mostly cosmetic surgeries in Matamoros, 170 were contacted, 104 reported epidurals, and 24 were diagnosed with Fusarium meningitis with 50% mortality. All cases shared the same anesthesiologist; WGS confirmed closely related strains, and guidance included consideration of fosmanogepix.
Impact: Defines a lethal outbreak linked to cosmetic procedure anesthesia with genomic confirmation, providing actionable guidance for diagnosis and therapy in at-risk patients.
Clinical Implications: Maintain high suspicion for fungal meningitis after any epidural anesthesia in medical tourists; promptly perform lumbar puncture and targeted fungal testing, and consider advanced antifungals (e.g., fosmanogepix) per evolving guidance.
Key Findings
- Of 233 potentially exposed individuals, 170 (73%) were contacted; 104 (61%) reported epidural anesthesia and 24 were diagnosed with Fusarium meningitis.
- Case fatality was 50% (12/24). All cases involved the same anesthesiologist in Mexico.
- Whole genome sequencing demonstrated closely related Fusarium isolates across the two implicated clinics; guidance updated to include fosmanogepix.
Methodological Strengths
- Multistate outbreak investigation with whole genome sequencing linking cases epidemiologically and genetically.
- Coordinated public health tracing with standardized data informing diagnostic and therapeutic guidance.
Limitations
- Incomplete ascertainment: only 29% of at-risk individuals underwent lumbar puncture; potential underdiagnosis.
- Observational design without a control group; reliance on contactability may introduce selection bias.
Future Directions: Standardize peri-procedural infection control for cosmetic clinics, develop rapid diagnostics for Fusarium CNS disease, and evaluate optimal antifungal regimens including novel agents in prospective studies.
BACKGROUND: Fungal meningitis outbreaks are rare and entail high mortality rates. Beginning May 2023, we investigated fungal meningitis caused by Fusarium solani species complex occurring in U.S. patients who received epidural anesthesia in Matamoros, Mexico. METHODS: Early epidemiological information suggested U.S. patients with suspected fungal meningitis had undergone mostly cosmetic procedures under epidural anesthesia performed in two Matamoros clinics. U.S. patients known to have received surgery at these clinics during January 1-May 13, 2023, (clinic closures date) were identified and notified by public health officials. Epidemiological and clinical data were used to update diagnostic and clinical guidance for outbreak response, including use of the experimental antifungal fosmanogepix. Whole genome sequencing was conducted on outbreak isolates. RESULTS: U.S. public health officials attempted to contact 233 potentially exposed U.S. residents who underwent surgeries, mostly cosmetic, in Mexico, reaching 170 (73%). Of those, 104 (61%) reported receiving epidural anesthesia and were therefore considered potentially at risk for fungal meningitis. At least 30/104 (29%) at-risk patients received a diagnostic lumbar puncture; 24 (23 women, 17 Hispanic or Latino) were diagnosed with fungal meningitis, and six were not. Twelve (50%) with fungal meningitis died. All cases involved epidural anesthesia administered by the same anesthesiologist in Mexico. Whole genome sequencing showed that patient isolates of Fusarium from the two implicated clinics in Matamoros, Mexico, were genetically closely related. CONCLUSIONS: Clinicians should maintain suspicion for fungal meningitis in patients with negative bacterial culture, viral culture and molecular testing with a history of epidural anesthesia for any reason.
3. Small EVs From Adipose-Derived MSCs Modulate Epidermal Barrier and Inflammation Via Sphingosine-1-Phosphate Signaling Pathway.
ASC-derived sEVs are enriched in sphingolipids and in enzymes that synthesize ceramide and sphingosine-1-phosphate (S1P) while lacking hydrolytic enzymes, suggesting they raise ceramide/S1P in recipient cells. In AD-model keratinocytes, sEVs suppressed proinflammatory cytokines and restored differentiation, implicating S1P signaling in barrier repair and inflammation control.
Impact: Identifies a lipid signaling mechanism (S1P) by which ASC-sEVs restore barrier and reduce inflammation, advancing EV-based therapeutics for inflammatory dermatoses.
Clinical Implications: Supports development of topical sEV formulations targeting sphingolipid pathways for atopic dermatitis and barrier dysfunction, and highlights S1P signaling as a therapeutic axis.
Key Findings
- ASC-sEVs are enriched in free fatty acids, ceramide, and sphingomyelin and exhibit higher levels of ceramide and S1P synthetic enzymes compared to donor cells.
- Hydrolytic enzymes for ceramide and S1P are lower in ASC-sEVs, suggesting elevated ceramide/S1P in recipient cells.
- In AD-model human keratinocytes, ASC-sEVs suppressed pro-inflammatory cytokines and restored keratinocyte differentiation.
Methodological Strengths
- ISEV-compliant sEV preparation with comparative lipidomics and enzyme profiling.
- Functional validation in human AD-model keratinocytes linking S1P signaling to barrier and inflammation outcomes.
Limitations
- Primarily in vitro with limited in vivo translational testing in this study.
- Donor variability and dosing/vehicle optimization for topical delivery were not fully addressed.
Future Directions: Test optimized topical sEV formulations in controlled in vivo models and early-phase trials, dissect S1P receptor subtype contributions, and assess long-term safety and manufacturing consistency.
Epidermal permeability barrier defects are associated with several skin diseases, including atopic dermatitis (AD). Using an AD mouse model, we previously demonstrated that topically administered small extracellular vesicles (sEVs) (prepared following the International Society of Extracellular Vesicles recommendations) from human adipose tissue-derived mesenchymal stem cells (ASC) ameliorate skin inflammation and normalize barrier function in parallel with increased ceramide (a key barrier lipid) production. To elucidate how ASC-sEVs alleviate these AD skin abnormalities, we characterized lipids and ceramide metabolic enzymes in ASC-sEVs versus donor ASCs. Our study revealed that free fatty acid, ceramide, and sphingomyelin are enriched in ASC-sEVs versus donor ASCs, while the synthetic enzymes of ceramide (and acidic sphingomyelinase), and sphingosine-1-phosphate (sphingosine kinase) are significantly higher in ASC-sEVs versus donor ASCs. Conversely, ceramide (ceramidase), and sphingosine-1-phosphate hydrolytic enzymes (sphingosine-1-phosphate lyase and sphingosine-1-phosphate phosphatase) are lower in ASC-sEVs, suggesting that ceramide and sphingosine-1-phosphate levels could elevate in cells that receive ASC-sEVs. ASC-sEV-mediated increases in sphingosine-1-phosphate suppress pro-inflammatory cytokine production in AD-model human keratinocytes. Additionally, keratinocyte differentiation, which is required for a competent epidermal permeability barrier, was restored in AD-model human keratinocytes treated with ASC-sEVs. Taken together, cells that endocytose ASC-sEVs can normalize epidermal permeability barrier function as well as alleviate inflammation by stimulating a sphingosine-1-phosphate signalling pathway.